Xanodyne wins bid for aaiPharma's pharmaceutical arm

Xanodyne Pharmaceuticals has emerged as the winning bidder for aaiPharma's pharmaceutical division. Xanodyne will pay $209 million and buy up to $30 million in services from aaiPharma. "We're extremely pleased that we've reached a favorable conclusion to the auction process," said aaiPharma's president and CEO Ludo Reynders. "This will significantly help the company in rebuilding its financial structure."

- read this press release for more

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.